Patients with advanced urothelial carcinoma live 3 months longer, on average, when given pembrolizumab as a second-line treatment instead of chemotherapy. The finding is based on data from the first phase III trial to test an immunotherapeutic in these patients, which could lead to another label indication for the PD-1 inhibitor.
http://ift.tt/2plA8CO
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου